Sitafloxacin

EXPERIMENTAL DRUGS / POTENTIAL ANTIBIOTIC THERAPIES AGAINST M. ULCERANS

Sitafloxacin

---

CLASS

Fluoroquinolones

---

TARGET PROTEIN

Bacterial DNA gyrase (topoisomerase II)

---

MECHANISM OF ACTION

Bacteriostatic (They impede DNA replication and transcription by hindering the DNA gyrase-catalyzed super-coiling of double-stranded DNA)

---

DRUG INTERACTION PHASE (APPROVED, INVESTIGATIONAL, EXPERIMENTAL)

Experimental

---

MODE OF ADMINISTRATION

Oral

---

LINK TO PUBMED

https://pubmed.ncbi.nlm.nih.gov/12407131/

https://pubmed.ncbi.nlm.nih.gov/32091697/

---

DRUG BANK ID

DB13261

---

EXTERNAL LINKS

ChemSpider 27471522

Wikipedia Sitafloxacin

---

REFERENCE

Dhople M., A., & Namba, K. (2002). In vitro activity of sitafloxacin (DU-6859a) alone, or in combination with rifampicin, against Mycobacterium ulcerans. The Journal of Antimicrobial Chemotherapy, 50(5), 727?729. https://doi.org/10.1093/JAC/DKF218



Pluschke, G., & R?ltgen, K. (2019). Buruli ulcer: Mycobacterium ulcerans disease. In Buruli Ulcer: Mycobacterium ulcerans Disease. https://doi.org/10.1007/978-3-030-11114-4

---